SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dinh dinh who wrote (7)5/14/1999 11:58:00 PM
From: glen  Read Replies (1) of 250
 
If Phase 3 trials are any where close to the results in Phase 2, then AISVAX vaccine could easily become THE PRODUCT that addresses the needs of what is a multi-billion dollar market. Although the IPO is new, (expected in July 1999),AIDVAX is well beyond its' early stages. Development of this vaccine began in 1985, achieving success in all phases of animal testing, and success in both Phase 1 and 2 of Human Clinical Trials. In addition, this vaccine is not necessarily a one use product. It may also be used as a booster to other potential AIDS vaccines, giving AIDSVAX even greater odds of becoming a staggering, huge financial success.

I don't follow ABGX well enough to comment. Welcome aboard SI, as I see that you joined today and have made your reply to VaxGen as your very first.

Regards,
glen
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News